The authors investigated the potential role of IgG N-glycosylation in Haemorrhagic Fever with Renal Syndrome (HFRS), which may offer significant insights for understanding molecular mechanisms and for ...

Etokimab (I-Mab Biopharma), which is optimized for common IL-33 gene polymorphisms, has completed patient recruitment in its Phase II trial. The strategic combination of IL-33 inhibitors with ...

A breach in the gut immunity and crossreactivity of the IgE antibodies with skin antigens or direct interaction with specific IgE, Fc receptors on Langerhans cells, mast cells, monocytes ...

Paclitaxel protein-bound, but not doxorubicin liposome injection, reduced the number of cells expressing Fc epsilon receptor I, the immunoglobulin E receptor. Researchers have developed and validated ...

Concentration-dependent reduction of expression of the high-affinity IgE Fc receptor, on bone marrow-derived mast cells from humanized mice. In vivo studies performed in mouse models demonstrate that ...

Recent lines of research are also trying to develop engineered proteins able to disrupt FceRI-IgE binding without crosslinking the receptor for example by using ankyrin repeated proteins (DARPins).

The allergic response in humans results from the crosslinking of IgE-Fc<; RI receptor complexes via the binding of IgE antibodies to antigens, which results in cell degranulation. The relationship ...

Turning to neonatal Fc receptors, Wright noted that these therapies are not targeting cytokines, but the “recycling” that occurs to prevent degradation of IgG.

Epsilogen, a producer of immunoglobulin E (IgE) antibodies to treat cancer, has published the final phase I data from the first ever clinical trial of an IgE antibody therapeutic. The results were ...